


Incidence, Kinetics, and Clinical Impact of Thrombocytopenia in Venovenous ECMO: Insights from the Multicenter Observational PROTECMO Study

Nina Buchtele, Kenichi Tanaka, Fabio Tuzzolino, Cara Agerstrand, Ali Ait Hssain, Jordi Riera, Peter Schellongowski, Matthieu Schmidt, Raj Ramanan, Martin Balik, Lars Mikael Broman, Nicolo Rizzitello, Konstanty Szuldrzyński, Whitney D Gannon, Vito Fanelli, Brian Trethowan, Hergen Buscher, Huda Alfoudri, Marco Giani, Alain Combes, Giacomo Grasselli, Roberto Lorusso, Antonio Arcadipane, Daniel Brodie, Gennaro Martucci; PROTECMO Study group

Background



Thrombocytopenia promotes bleeding during VV ECMO


Methods & Aim




652 adult VV ECMO patients from the multicenter, prospective PROTECMO study

- Incidence
- Risk factors
- Clinical relevance

Of thrombocytopenia
& platelet transfusions
during ECMO




Results




80,2% of patients had any degree of thrombocytopenia during ECMO


A $10 \cdot 10^9/L$ decrease in platelet count was associated with a 3.7% (95% CI: 2.4–5.0%) increase in risk of bleeding




Risk factors for thrombocytopenia $<100 \cdot 10^9/L$




ICU days
prior ECMO




Post-OP
admission



Immunosuppression



Renal replacement
therapy



Septic shock